News Search & Analytics
US Edition
Minimum 3 characters required!!
Report Based On Past 7 Days Data
4
Total Articles
1
Total Publisher Covering articles
3
Highest On 2017-08-09
0
Articles Got Popular On Social Media
gilead sciences found in Articles in last 7 Days

Top Articles

June 19 Gilead Sciences Inc * Gilead receives approval in Canada for Vemlidy™ (tenofovir alafenamide) for the treatment of chronic hepatitis b virus infection * Gilead Sciences Inc...
Oct 20 Gilead Sciences Inc : * Gilead announces top-line phase 2 results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and...
Oct 20 Gilead Sciences Inc * Gilead announces SVR12 rates from four phase 3 studies of a once-daily, fixed-dose combination of Sofosbuvir, Velpatasvir and Voxilaprevir in treatment...
Sept 27 Gilead Sciences * Gilead Sciences and the World Health Organization announce five-year visceral leishmaniasis collaboration * Partnership with World Health Organization to ...
Oct 20 (Reuters) - Gilead Sciences Inc : * Gilead announces top-line phase 2 results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertensi...
Nov 16 Gilead Sciences Inc : * Gilead Sciences Inc - non-inferiority was not achieved for key secondary endpoint of response rate in total symptom score (TSS) * Gilead announces to...
BRIEF-Gilead presents new phase 2 data on Bictegravir
-Reuters - Mon Feb 13 14:05:30 EST 2017
Feb 13 Gilead Sciences Inc : * Gilead presents new phase 2 data on Bictegravir, an investigational integrase strand transfer inhibitor for the treatment of HIV * Bictegravir in com...
After boosting its full-year hepatitis C revenue guidance last month, Gilead Sciences' (NASDAQ: GILD) share price has been rallying. However, the Food and Drug Administration appro...
Why Gilead Sciences Shares Fell 7% in October | Fox Business
-Fox Business - Tue Nov 08 13:53:26 EST 2016
Image source: Getty Images. Worries that hepatitis C sales will remain a headwind to top- and bottom-line growth caused Gilead Sciences (NASDAQ: GILD) shares to decline 7% in Octob...
Gilead Sciences Inc. said pre-market Tuesday that an HIV drug combination met primary endpoints in four late-stage clinical trials. The company said it plans to file for approval i...
BRIEF-Gilead Sciences prices $5 bln of senior unsecured notes
-Reuters - Thu Sep 15 20:14:16 EDT 2016
Sept 15 Gilead Sciences Inc : * Gilead prices $5 billion of senior unsecured notes * Priced $1.25 billion of 2.950% senior notes maturing in 2027 * Priced $750 million of 2.500% se...
After Rough Patch,Gilead Shouldn't Succumb to Deal Pressure
-The Wall Street Journal - Sun Nov 20 11:00:57 EST 2016
Gilead Sciences shareholders have faced unrelenting disappointment lately. The rough ride isn’t a reason to abruptly change its deal strategy, though. The latest blow: Gilead annou...
Gilead's Boom Fades and --- Will Linger
-The Wall Street Journal - Wed Feb 08 07:14:15 EST 2017
Gilead Sciences, perhaps the company most responsible for powering the last biotech bull market, has a revenue problem on its hands. Its struggles highlight how quickly the moment ...
Gilead Goes to the Head of the Line
-The Wall Street Journal - Tue Feb 21 10:11:23 EST 2017
A lack of deal activity at Gilead Sciences Inc. has lately frustrated shareholders. But company executives know a bargain when they see one. The biotech giant purchased a priority ...
Why You're Right to Invest in Gilead Sciences Stock | Fox Business
-Fox Business - Mon Jan 30 10:04:15 EST 2017
With the Dow Jones Industrial Average blasting through the 20,000 mark, many stocks are currently trading at or near their all-time highs. Unfortunately, biotechnology investors ha...
Investors have turned to the pharmaceutical industry for solid dividend stocks for a long time. However, biotechs typically weren't high on the list when it came to dividends. Over...
The Pros and Cons of Buying Gilead Sciences Stock | Fox Business
-Fox Business - Thu Sep 22 08:04:46 EDT 2016
Image source: Stockmonkeys.com via Flickr. Gilead Sciences (NASDAQ: GILD) is a biotech Goliath generating $30 billion in annualized sales and $14 billion in annualized net income. ...
Gilead Sciences Inc. makes the two leading drugs that can quickly cure hepatitis C infections. But most patients can't afford the expensive drugs, and states restrict their use amo...
Gilead poaches Novartis cancer specialist Riva
-Reuters - Wed Jan 04 01:27:39 EST 2017
ZURICH Gilead Sciences has hired a top cancer specialist from Swiss drugmaker Novartis as the U.S. healthcare group sharpens its focus on oncology. Alessandro Riva will become a Gi...
Should Investors Bet on Gilead Sciences Version 3.0? | Fox Business
-Fox Business - Sat Jan 14 13:03:53 EST 2017
Intercept Pharmaceuticals (NASDAQ: ICPT) CEOMark Pruzanski presented late Wednesday at the J.P. Morgan Healthcare Conference. Pruzanski obviously focused on Intercept's achievement...
What to Expect From Gilead Earnings
-24/7 Wall St. - Tue Feb 07 07:10:13 EST 2017
Gilead Sciences Inc. (NASDAQ: GILD) is set to report its fourth-quarter financial results after the markets close on Tuesday. The consensus estimates call for $2.61 in earnings per...
BRIEF-GlobeImmune announces updates
-Reuters - Thu Nov 17 13:29:08 EST 2016
Nov 17 GlobeImmune Inc * GlobeImmune announces updates * GlobeImmune Inc says Gilead Sciences Inc has terminated collaboration and license agreement with company * GlobeImmune Inc ...
3 Charts That Show Why to Buy Gilead Sciences Stock Now | Fox Business
-Fox Business - Sun Jul 02 08:03:51 EDT 2017
Probably every investor interested in biotech knows all of the challenges facing Gilead Sciences (NASDAQ: GILD). Its once high-flying stock has been beaten down over the last coupl...
Deal or no deal? No, this isn't a reference to the once-popular TV game show. Instead, it's the question that investors are asking about Gilead Sciences (NASDAQ: GILD). The big bio...
Why Gilead Sciences Lost a Staggering 29.2% In 2016 | Fox Business
-Fox Business - Thu Jan 05 04:03:38 EST 2017
Image source: Getty Images. Following disappointing sales of its hepatitis C drugs and amid discouraging pipeline failures,Gilead Sciences(NASDAQ: GILD)shares lost 29.2% of their v...
Gilead Sciences Inc. has been ordered to pay Merck & Co. $2.54 billion in royalties in a patent lawsuit over Gilead’s blockbuster hepatitis C drugs Sovaldi and Harvoni. A feder...
Better Buy: Gilead Sciences Inc. vs. Pfizer Inc. | Fox Business
-Fox Business - Wed Nov 09 13:04:45 EST 2016
Your time horizon matters when picking a stock. Gilead Sciences (NASDAQ: GILD), for example, gave investors five times the returns of Pfizer (NYSE: PFE) over the past five years. I...
The numbers didn't lie: Gilead Sciences (NASDAQ: GILD) posted pretty good second-quarter results. While revenue and earnings fell compared to the prior-year period, the big bi...
I f at first you don’t succeed … After losing one challenge to Gilead Sciences patents on hepatitis C drugs in India, patient advocacy groups are now challenging still other patent...
Gilead's Q3 Bombshell: No More Hepatitis C R&D | Fox Business
-Fox Business - Wed Nov 02 14:05:12 EDT 2016
Gilead Sciences (NASDAQ: GILD) is a Goliath in hepatitis C treatment; however, the company is shifting its research spending in the future away from hepatitis C to other indication...
Advertisement
Publishers
Number of articles

4